
Triple agonist designed to outperform GLP-1 drugs for obesity
Protagonist Therapeutics has announced a new, highly potent oral triple agonist peptide development candidate for obesity. With once-daily dosing, PN-477o targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors. The company has announced it will also develop a subcutaneous version, PN-477sc, as… Read More
